A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2018

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
LymphomaLeukemia
Interventions
DRUG

CPI-613

CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)

Trial Locations (11)

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

19104

University of Pennsylvania (Data Collection Only), Philadelphia

77030

Md Anderson Cancer Center, Houston

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

All Listed Sponsors
collaborator

City of Hope Medical Center

OTHER

collaborator

Massachusetts General Hospital

OTHER

collaborator

M.D. Anderson Cancer Center

OTHER

collaborator

George Washington University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03793140 - A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations | Biotech Hunter | Biotech Hunter